Nashville Early Diagnosis Lung Cancer Project

Lung Cancer Clinical Trial

Official title:

Nashville Early Diagnosis Lung Cancer Project

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01475500
• Other study ID #: VICC THO 1078
• Secondary ID: U01CA152662
• Status: Active, not recruiting
• Start date: April 2011
• Est. completion date: November 30, 2026

Study information

• Verified date: December 2023
• Source: Vanderbilt-Ingram Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This screening study will address the lack of molecular strategies for the early detection of lung cancer and integrate those with epidemiological and imaging strategies.

The hypothesis is that the repeated measure of biomarkers of risk obtained from the molecular analysis of biological specimens including those from bronchoscopy (bronchial brushings and biopsies) may contribute to the refinement of high-risk populations and allow an earlier clinical diagnosis.

The goal of the investigators study is to provide screening for lung cancer in a high-risk population. In this prospective cohort it will be tested whether repeated measure of biomarkers of risk allows early detection of lung cancer.

Description:

It is proposed to test the hypotheses in a screening study of high risk individuals (characterized by an established prediction rule). The expected prevalence of lung cancer in this high risk group is estimated to be 2% per year. All individuals benefit from clinic visit, low-dose Chest CT, spirometry and auto-fluorescence bronchoscopy at baseline, Chest CT, follow-up doctor visit, and auto-fluorescence bronchoscopy at least at year 2 and 5.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 480
• Est. completion date: November 30, 2026
• Est. primary completion date: October 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 80 Years

Eligibility

Inclusion Criteria:

• 55 - 80 years of age

• Current smoker or former smoker. If former smoker, must have quit smoking less than 15 years ago

• >/= 30 pack year of smoking history

Exclusion Criteria:

• History of diagnosis/treatment of lung cancer in the past 2 years

• History of head/neck or esophageal cancer in the last 1 year

• Inability to provide informed consent

• Participants in whom stopping anti-platelet or anti-coagulation therapy would have an adverse effect (DVT, mechanical heart valves, unstable coronary syndrome, etc.)

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Procedure:
• Sputum sample
This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
• Pulmonary function tests
A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.

Radiation:
• Computerized tomography (CT) scan of the chest
A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.

Other:
• Buccal epithelium collection
Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.

Procedure:
• Nasal brushings
A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
• Bronchoscopy
A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
• Bronchoalveolar lavage
During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
• Blood sample collection
A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
• Urine sample
Urine will be collected for routine urine tests at baseline and yearly to year 5.
• Questionnaire-data collection
A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.

Locations

Country	Name	City	State
United States	Vanderbilt University, Vanderbilt-Ingram Cancer Center	Nashville	Tennessee
United States	Veterans Administration	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt-Ingram Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To compare candidate biomarkers over time among participants who did and did not develop lung cancer	Blood, sputum, urine, nasal washings, buccal epithelium, endobronchial tissue, and bronchioalveolar washings are examined for biomarkers present in patients who develop lung cancer compared with those patients who do not develop lung cancer. Baseline and yearly screening results will be compared in the two groups.	at baseline and yearly to year 5
Secondary	To identify and validate new biomarkers that are associated with lung cancer risk factors and premalignant lesions.	Blood, sputum, urine, nasal washings, buccal epithelium, endobronchial tissue, and bronchioalveolar washings are examined for presently unknown biomarkers that occur in patients with lung cancer and in patients who do not have lung cancer but who may be at further increased risk of lung cancer.	at baseline and yearly to year 5
Secondary	To assess changes in prevalence and grade of pre-invasive lesions in this cohort.	Endobronchial tissue will be examined under a microscope for presence of changes in the cells that are abnormal but which are not invasive cancer.	baseline, at years 2 and 5 (abnormal tissue will re-examined every 6 months)
Secondary	To describe patients eligible for future chemoprevention clinical trials.	Inclusion criteria for those patients who, based on their biomarker profile, are at increased risk of invasive lung cancer and who may benefit from clinical trials that will study chemoprevention strategies for lung cancer.	at year 5